Trials / Active Not Recruiting
Active Not RecruitingNCT05291871
Immunogenicity of Fractional Dose of the HPV Vaccines
- Status
- Active Not Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 92 (actual)
- Sponsor
- University of Washington · Academic / Other
- Sex
- All
- Age
- 27 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This randomized phase IV trial compares intramuscular and intradermal fractional dose of bivalent HPV vaccine to fractional dose of nonavalent HPV vaccine among men and women aged 27-45 years in Seattle, Washington. Participants will have immune response assessed at baseline, 4 weeks, 6 months, and 12 months
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | HPV vaccine | One-fifth dose bivalent HPV Vaccine or One-fifth dose nonavalent HPV Vaccine |
Timeline
- Start date
- 2022-06-15
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
- First posted
- 2022-03-23
- Last updated
- 2025-03-27
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05291871. Inclusion in this directory is not an endorsement.